New & Noteworthy

April 2016

Quality Assurance Program and Consulting Services

CAPS (A B. Braun Company)

Central Admixture Pharmacy Services, Inc (CAPS) introduces its new 503B quality assurance program and consulting service. CAPS’ two 503B-registered outsourcing facilities have been designated for anticipatory compounding needs, including controlled substances, anesthesia syringes, and drug delivery. The company’s new Test, Hold, and Release (THR) program ensures every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new FDA specifications for sterility, potency, and endotoxin testing prior to release and shipment. In addition, the company announces its new consulting service, with a team of compounding experts available to help pharmacies reach compliance. The ReadyCheck quality assurance program is an onsite USP <797> compliance analysis performed by two auditors who examine eight categories  (encompassing 200 criteria) including compounding, dispensing, cleanroom processes, testing and monitoring, media fills, and training.

Request More Information

Current Issue